Burden of disease in pediatric narcolepsy: a claims-based analysis of health care utilization, costs, and comorbidities.


Journal

Sleep medicine
ISSN: 1878-5506
Titre abrégé: Sleep Med
Pays: Netherlands
ID NLM: 100898759

Informations de publication

Date de publication:
02 2020
Historique:
received: 14 03 2019
revised: 12 08 2019
accepted: 14 08 2019
pubmed: 17 12 2019
medline: 20 4 2021
entrez: 17 12 2019
Statut: ppublish

Résumé

This study analyzed a privately insured pediatric population with and without narcolepsy to determine the impact of pediatric narcolepsy on comorbidities, health care utilization, and cost. Additional analyses compared narcolepsy type 1 and type 2. This retrospective cross-sectional study identified US patients with narcolepsy <18 years of age with ≥2 claims with a diagnosis code of narcolepsy using Truven MarketScan® data 2011 to 2015. Patients were matched to controls without narcolepsy. Comorbid conditions, health care utilization, and costs were measured by calendar year. P values are nominal, and no adjustments for multiplicity or multiple comparisons were made. A total of 1427 pediatric patients with narcolepsy were identified and matched with 4281 controls from 2011 to 2015. Patients with narcolepsy had more comorbid conditions (mean 5.8 vs 2.4, nominal P < 0.001). Respiratory diseases and mood disorders were more common in patients with narcolepsy than controls (57% vs 32% and 56% vs 14%, respectively; both nominal P < 0.001). Compared to controls, patients with narcolepsy underwent more diagnostic tests (electroencephalogram, EEG [0.13 vs 0.0053]) and brain computed tomography, CT/magnetic resonance imaging, MRI (0.26 vs 0.022; both nominal P < 0.001). Mean annual inpatient days (0.71 vs 0.15), emergency department visits (0.51 vs 0.15), and outpatient office visits (8.6 vs 2.3) were higher for patients with narcolepsy than controls (all nominal P < 0.001). Annual mean health care costs were higher for patients with narcolepsy versus controls ($15,797 vs $2449, nominal P < 0.001). Pediatric patients with narcolepsy had greater comorbidity, higher health care utilization, and higher costs than patients without narcolepsy.

Sections du résumé

BACKGROUND
This study analyzed a privately insured pediatric population with and without narcolepsy to determine the impact of pediatric narcolepsy on comorbidities, health care utilization, and cost. Additional analyses compared narcolepsy type 1 and type 2.
METHODS
This retrospective cross-sectional study identified US patients with narcolepsy <18 years of age with ≥2 claims with a diagnosis code of narcolepsy using Truven MarketScan® data 2011 to 2015. Patients were matched to controls without narcolepsy. Comorbid conditions, health care utilization, and costs were measured by calendar year. P values are nominal, and no adjustments for multiplicity or multiple comparisons were made.
RESULTS
A total of 1427 pediatric patients with narcolepsy were identified and matched with 4281 controls from 2011 to 2015. Patients with narcolepsy had more comorbid conditions (mean 5.8 vs 2.4, nominal P < 0.001). Respiratory diseases and mood disorders were more common in patients with narcolepsy than controls (57% vs 32% and 56% vs 14%, respectively; both nominal P < 0.001). Compared to controls, patients with narcolepsy underwent more diagnostic tests (electroencephalogram, EEG [0.13 vs 0.0053]) and brain computed tomography, CT/magnetic resonance imaging, MRI (0.26 vs 0.022; both nominal P < 0.001). Mean annual inpatient days (0.71 vs 0.15), emergency department visits (0.51 vs 0.15), and outpatient office visits (8.6 vs 2.3) were higher for patients with narcolepsy than controls (all nominal P < 0.001). Annual mean health care costs were higher for patients with narcolepsy versus controls ($15,797 vs $2449, nominal P < 0.001).
CONCLUSION
Pediatric patients with narcolepsy had greater comorbidity, higher health care utilization, and higher costs than patients without narcolepsy.

Identifiants

pubmed: 31841742
pii: S1389-9457(19)30289-8
doi: 10.1016/j.sleep.2019.08.008
pii:
doi:

Types de publication

Journal Article Research Support, Non-U.S. Gov't

Langues

eng

Sous-ensembles de citation

IM

Pagination

110-118

Informations de copyright

Copyright © 2019 Elsevier B.V. All rights reserved.

Auteurs

Ginger Carls (G)

Medical Affairs, Jazz Pharmaceuticals, Inc., 3170 Porter Dr, Palo Alto, CA 94304, USA. Electronic address: gingercarls@gmail.com.

Sheila Reiss Reddy (SR)

Partnership for Health Analytic Research, LLC, 280 South Beverly Dr, Beverly Hills, CA 90212, USA. Electronic address: srreddy@pharllc.com.

Michael S Broder (MS)

Partnership for Health Analytic Research, LLC, 280 South Beverly Dr, Beverly Hills, CA 90212, USA. Electronic address: mbroder@pharllc.com.

Ryan Tieu (R)

Partnership for Health Analytic Research, LLC, 280 South Beverly Dr, Beverly Hills, CA 90212, USA. Electronic address: ryanstieu@gmail.com.

Kathleen F Villa (KF)

Medical Affairs, Jazz Pharmaceuticals, Inc., 3170 Porter Dr, Palo Alto, CA 94304, USA. Electronic address: Kathleen.Villa@jazzpharma.com.

Judi Profant (J)

Medical Affairs, Jazz Pharmaceuticals, Inc., 3170 Porter Dr, Palo Alto, CA 94304, USA. Electronic address: Judith.Profant@jazzpharma.com.

Ann C Halbower (AC)

University of Colorado School of Medicine, 13001 E 17th Pl, Aurora, CO 80045, USA. Electronic address: Ann.Halbower@childrenscolorado.org.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH